All In Biotech

Drug Trial Radar · NCT03105128

A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study of the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease

Last checked: Nov 20, 2026Latest source record: Jul 6, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 931 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

931

Actual

Start

May 10, 2017

Primary completion

Nov 9, 2020

Study completion Apr 14, 2021

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Apr 7, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 16 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of risankizumab versus placebo during induction therapy in participants with moderately to severely active Crohn's disease (CD).

Conditions

  • Crohn's Disease

Interventions

  • placebo for risankizumabDrug

    Placebo for risankizumab administered by intravenous infusion

  • risankizumab IVDrug

    Risankizumab administered by intravenous infusion

  • risankizumab SCDrug

    Risankizumab administered by subcutaneous (SC) injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical RemissionTime frame: Week 12
  2. US Specific: Percentage of Participants With Endoscopic ResponseTime frame: Week 12
  3. Global Outside of US: Percentage of Participants With Clinical RemissionTime frame: Week 12
  4. Global Outside of US: Percentage of Participants With Endoscopic ResponseTime frame: Week 12

Locations

475 sites in 44 countries. Site status is shown where the registry gives one.

  • Phoenix VA Health Care System /ID# 162267

    Phoenix, Arizona

  • HonorHealth Research Institute - Shea /ID# 161783

    Scottsdale, Arizona

  • Digestive Disease Consultants, A Division of Arizona Digestive Health, P.C /ID# 211883

    Tempe, Arizona

  • University of Arizona /ID# 158469

    Tucson, Arizona

  • Atria Clinical Research /ID# 164740

    Little Rock, Arkansas

  • Newport Huntington Medica /ID# 213033

    Huntington Beach, California

  • United Medical Doctors /ID# 207040

    Los Alamitos, California

  • TLC Clinical Research Inc /ID# 212503

    Los Angeles, California

  • Gastrointestinal Biosciences Clinical Trials, LLC /ID# 162656

    Los Angeles, California

  • United Medical Doctors - Murrieta /ID# 158424

    Murrieta, California

  • Southern CA Research Ctr., Inc /ID# 167875

    Riverside, California

  • University of California, San Francisco /ID# 157143

    San Francisco, California

  • Cedars-Sinai Medical Center-West Hollywood /ID# 163842

    West Hollywood, California

  • Peak Gastroenterology Associates, PC /ID# 165834

    Colorado Springs, Colorado

  • Rocky Mountain Pediatric Gastroenterology /ID# 207169

    Lone Tree, Colorado

  • Western Connecticut Medical Group /ID# 165849

    Danbury, Connecticut

  • Seffner Premier Health Care, PA /ID# 162265

    Brandon, Florida

  • Clinical Research of West Florida, Inc /ID# 204859

    Clearwater, Florida

  • Clinical Research of West Florida, Inc /ID# 207450

    Clearwater, Florida

  • South Lake Pain Institute, Inc /ID# 162825

    Clermont, Florida

  • Universal Axon Clinical Research /ID# 165432

    Doral, Florida

  • Nature Coast Clinical Research - Inverness /ID# 159414

    Inverness, Florida

  • SIH Research Mumtaz, Inc /ID# 163082

    Kissimmee, Florida

  • Alliance Medical Research /ID# 163840

    Lighthouse PT, Florida

  • Cfagi Llc /Id# 201571

    Maitland, Florida

  • Vista Health Research, LLC /ID# 212664

    Miami, Florida

  • ITB Research /ID# 161334

    Miami, Florida

  • Coral Research Clinic /ID# 158549

    Miami, Florida

  • South Florida Research Ph I-IV, Inc. /ID# 161836

    Miami, Florida

  • Gastroenterology Group Naples /ID# 165206

    Naples, Florida

  • Advanced Research Institute, Inc /ID# 161959

    New Port Richey, Florida

  • Endoscopic Research, Inc. /ID# 205901

    Orlando, Florida

  • Omega Research Maitland, LLC /ID# 171081

    Orlando, Florida

  • IMIC Inc. Medical Research /ID# 154943

    Palmetto Bay, Florida

  • Clinical Research Trials of Florida, Inc. /ID# 201014

    Tampa, Florida

  • Gastroenterology Associates of Central Georgia, LLC /ID# 154857

    Macon, Georgia

  • Northwestern University Division of GI/Hepatology /ID# 158283

    Chicago, Illinois

  • The University of Chicago Medical Center /ID# 157141

    Chicago, Illinois

  • NorthShore University HealthSystem /ID# 158287

    Evanston, Illinois

  • Southwest Gastroenterology /ID# 165002

    Oak Lawn, Illinois

Showing 40 of 475 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.